Celerion, a global leader in clinical pharmacology and bioanalytical sciences, announces a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies. Celerion is a critical partner in bringing new medicines to market. The company is a premier provider of clinical pharmacology and advanced bioanalytical sciences, specializing in first-in-human dose escalation, cardiac safety (TQT), bioequivalence, drug-drug interaction, renal and hepatic impairment, PK/PD characterization, and other complex clinical pharmacology studies that are critical to drug labeling and regulatory approval.
Read the full article: Celerion Announces Majority Investment from THL Partners //
Source: https://thl.com/articles/celerion-announces-majority-investment-from-thl-partners/